Solensia 7 mg/ml Solution for Injection for Cats

Continuation of treatment should be based on the individual response of each animal. If
a positive response is not observed, consider alternative treatments.

Revised: February 2025
AN: 03538/2024
This veterinary medicinal product may induce transient or persistent anti-drug
antibodies. The induction of such antibodies may reduce the efficacy of the product
although this was not observed during the 84 days of the pivotal clinical trial. No
information is available for longer duration treatment.

i) Special precautions for use in animals
The safety and efficacy of this product has not been investigated in cats with kidney
disease IRIS stages 3 and 4. Use of the product in such cases should be based on a
benefit-risk assessment performed by the responsible veterinarian.
ii) Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of
accidental self-injection. Repeated accidental self-administration may increase the risk
of hypersensitivity reactions.
The importance of Nerve Growth Factor (NGF) in ensuring normal foetal nervous
system development is well-established and laboratory studies conducted on non-
human primates with human anti-NGF antibodies have shown evidence of reproductive
and developmental toxicity. Pregnant women, women trying to conceive, and
breastfeeding women should take extreme care to avoid accidental self-injection.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
iii) Other precautions
Not applicable.